Genome & Company (KOSDAQ:314130)
3,560.00
-200.00 (-5.32%)
At close: Jul 6, 2026
Genome & Company Market Cap
Genome & Company has a market cap or net worth of 160.83 billion as of July 7, 2026. Its market cap has increased by 75.09% in one year.
Market Cap
160.83B
Enterprise Value
140.83B
Revenue
24.02B
Ranking
n/a
PE Ratio
n/a
Stock Price
3,560.00
Market Cap Chart
Since December 26, 2018, Genome & Company's market cap has increased from 71.88B to 160.83B, an increase of 123.76%. That is a compound annual growth rate of 11.29%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 6, 2026 | 160.83B | -32.53% |
| Dec 30, 2025 | 238.38B | 179.77% |
| Dec 30, 2024 | 85.21B | -51.64% |
| Dec 28, 2023 | 176.21B | -28.34% |
| Dec 29, 2022 | 245.90B | -47.55% |
| Dec 30, 2021 | 468.83B | -55.28% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 26, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| curacle co.,ltd. | 247.13B |
| Kangstem Biotech | 244.54B |
| NIBEC | 193.14B |
| Kanaph Therapeutics | 192.34B |
| Y-Biologics | 178.19B |
| Ensol Biosciences | 172.98B |
| Prestige Biologics | 154.73B |
| Bio Solution | 152.50B |